Source: Business Insider
Loxo Oncology CEO Josh Bilenker sold his company to pharma giant Eli Lilly in January 2019 in an $8 billion deal that came together in just 18 days. A year later, Bilenker is still with Lilly, serving as the company’s head of oncology research under the Loxo Oncology name. “I think founders, if they care about the medicines they help create, should care about seeing them approved and launched,” Bilenker said Click here for more BI Prime stories . It’s been a year since Loxo Oncology sold itself to Eli Lilly for $8 billion, after a whirlwind 18-day sale process. And in an unusual turn, Loxo CEO Josh Bilenker is still with the company. It’s not uncommon for biotechs to be acquired and absorbed into the development pipelines of larger pharmaceutical companies, at which point the executive teams depart to join other endeavors. Read more: The inside story of Eli Lilly’s 18-day race to secure an $8 billion deal in time for the ‘Super Bowl’ of healthcare But in the case of Loxo, Bilenker, along with Jake Van Naarden, Loxo’s chief business officer and Nisha Nanda, Loxo’s chief development officer, have stayed on to lead the business unit.